{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.84","value":"1.8"},{"groupId":"OG001","spread":"29.30","value":"1.5"}]}],"title":"Loss of Appetite (n=304, 242)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.15","value":"6.3"},{"groupId":"OG001","spread":"25.29","value":"3.5"}]}],"title":"Fatigue (n=302, 242)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.05","value":"-7.8"},{"groupId":"OG001","spread":"25.74","value":"-9.1"}]}],"title":"Cough (n=303, 243)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.52","value":"-2.8"},{"groupId":"OG001","spread":"25.27","value":"-1.8"}]}],"title":"Dyspnea (n=305, 244)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.98","value":"-3.3"},{"groupId":"OG001","spread":"17.22","value":"-2.2"}]}],"title":"Pain (n=302, 243)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.19","value":"-0.3"},{"groupId":"OG001","spread":"26.92","value":"-0.6"}]}],"title":"Overall Symptoms (n=303, 242)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.74","value":"3.8"},{"groupId":"OG001","spread":"26.79","value":"2.2"}]}],"title":"Interference (n=306,241)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.35","value":"-0.3"},{"groupId":"OG001","spread":"24.71","value":"-1.6"}]}],"title":"Quality of Life (n=305, 243)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.55","value":"-1.9"},{"groupId":"OG001","spread":"16.52","value":"-1.5"}]}],"title":"Average Symptom Burden Index (ASBI) (n=294, 234)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.03","value":"-0.8"},{"groupId":"OG001","spread":"16.17","value":"-0.8"}]}],"title":"LCSS Total Score (n=290, 228)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"545"},{"groupId":"OG001","value":"548"}],"units":"Participants"}],"description":"The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms \\[loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain\\] and 3 items were global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-mm lines. A higher score for any item represented a higher level of symptoms/problems. Scores for each of the reported categories ranged from 0 (for best outcome) to 100 (for worst outcome). The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom items of the LCSS, and the Total LCSS was the mean of all 9 LCSS items. ASBI and Total LCSS were not computed for a participant if he/she had 1 or more missing values for the 6 and 9 items, respectively.","dispersionType":"Standard Deviation","groups":[{"description":"Necitumumab + Gemcitabine + Cisplatin\n\nNecitumumab: 800 mg I.V. infusion on Days 1 and 8 of every 3 week cycle.\n\nContinues until progressive disease, toxicity, noncompliance, or withdrawal.\n\nGemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.\n\nContinues for a maximum of six cycles.\n\nCisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.\n\nContinues for a maximum of six cycles.","id":"OG000","title":"Necitumumab + Gemcitabine + Cisplatin"},{"description":"Gemcitabine + Cisplatin\n\nGemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.\n\nContinues for a maximum of six cycles.\n\nCisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.\n\nContinues for a maximum of six cycles.","id":"OG001","title":"Gemcitabine + Cisplatin"}],"paramType":"MEAN","populationDescription":"All randomized participants who had evaluable data for LCSS.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 6 (Cycle = 3 Weeks)","title":"Mean Change From Baseline in PRO Using the Outcomes Lung Cancer Symptom Scale (LCSS)","type":"SECONDARY","unitOfMeasure":"millimeter (mm)"}